source
- Altimmune’s pemvidutide cuts heavy drinking days in phase 2 AUD trialAltimmune announced that its experimental dual GLP-1/glucagon receptor agonist pemvidutide reduced heavy drinking in a phase‑2 study of alcohol use disorder. In the 24‑week Reclaim trial, particip…
- Altimmune's pemvidutide cuts heavy drinking days in Phase 2 trialAltimmune reported that its experimental GLP-1/GIP injection pemvidutide achieved its primary and key secondary goals in a Phase 2 study of alcohol use disorder. The double-blind trial enrolled 10…